Spiral Therapeutics, a South San Francisco, CA-based clinical-stage company focused on delivering therapies for inner ear disorders, raised $8.25M in funding.
The round was led by Savoir Capital and Catalio Capital Management with participation from Humboldt Fund, Savoir Capital and Catalio Capital Management.
The company intends to use the funds for the continuing development of its lead candidate, SPT-2101, for the treatment of inner ear inflammation.
Led by Hugo Peris, Founder and CEO, Spiral Therapeutics is a clinical-stage company focused on delivering therapies for inner ear disorders. Its novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea. The company is advancing a therapeutic pipeline with focus on hearing loss and balance disorders. Its lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of inner ear inflammation.
FinSMEs
09/01/2023